ClinicalTrials.gg
CompletedNCT03556956Updated Dec 8, 2020

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

A Phase 2/3 interventional study of Masitinib in Colorectal Cancer Metastatic, sponsored by AB Science. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by AB Science · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2020.
  • Registered 2 years 11 months after the study started (first participant enrolled Jul 2015, registered Jun 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Colorectal Neoplasms with a site in Czechia — 8 open to participants now, 18 under way, 7 of them phase 3. Colorectal Neoplasms · Czechia.

Enrollment
49th of 67
219 · median 461
Started
2015
with 1 other
Phase 2/3
3 of 76
1 open now
Registered
44th of 76
by date

Among the 76 studies in Colorectal Neoplasms with a site in Czechia, this one is the 49th largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 2/3, and was the 44th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

8 of the 76 studies in Colorectal Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Colorectal Neoplasms with a site in Czechia, or all of them as a file.
02

Study summary

A prospective, multicentre, open-label, randomized, phase 2-3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care, in third or fourth line treatment of patients with metastatic colorectal cancer

Read the detailed description

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care in third or fourth line treatment of patients with metastatic colorectal cancer.

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with non-resectable colorectal cancer with histological or cytological documentation of adenocarcinoma of the colon or rectum.
  • Patient in or fourth line of treatment for metastatic colorectal cancer.
  • Patient with according to criteria (version 1.1).
  • Patient with equal to or less than 2.
  • Patient with adequate organ function
  • Other inclusion criteria may also apply

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with masitinib, or any other tyrosine kinase inhibitor for the treatment of , except regorafenib.
  • More than 3 prior chemotherapy regimens for colorectal cancer.
  • Pregnant, intent to be pregnant, or nursing female patient
  • Patient with any chronic inflammatory bowel disease
  • Patient treated for a cancer other than colorectal cancer within five years before enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.
  • Other exclusion criteria may also apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Masitinib plus FOLFIRI

    Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid). Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal.

    Drug: Masitinib

  • No intervention
    Best Supportive Care

    Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.

Interventions

  • Tyrosine kinase inhibitor

    Also known as: AB1010

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival (0S) is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

Secondary outcomes

  1. Survival rates

    Survival rate, defined as the proportion of patients alive at each time point, estimated with Kaplan-Meier distribution

    Time frame: Every 24 weeks, assessed up to 60 months

  2. Progression Free Survival (PFS)

    Progression Free Survival (PFS) is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by the investigator on CT scan according to RECIST 1.1 criteria.

    Time frame: From day of randomization to disease progression or death, whichever came first, assessed up to 60 months

07

Study locations

5 sites
  • University Hospital Olomouc
    Olomouc, 779 00, Czechia
  • Chu - Hopitaux de Rouen
    Rouen, France
  • Omsk Clinical oncology dispensary
    Omsk, 644013, Russian Federation
  • Hospital Madrid Norte San Chinarro
    Madrid, Spain
  • Hammersmith Hospital Imperial College Healthcare Nhs Trust
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Dec 2020, 65 months.

Of 36 phase 2/3 interventional studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 105. This study's 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2018
First posted
Jun 14, 2018
StartActual
Jul 2015
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Results delay requested
Dec 7, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03556956
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
Jul 2015
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Dec 8, 2020

Study contacts

Julien Taieb, MD
principal investigator · Hôpital Européen Georges Pompidou, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion